Literature DB >> 15155189

Reactivity of platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum.

Nina Singh1, Asia Obman, Shahid Husain, Sherrie Aspinall, Sue Mietzner, Janet E Stout.   

Abstract

The possible reactivities of commonly used antibiotics of fungal, nonfungal, and nonmicrobial or synthetic sources with the Platelia Aspergillus galactomannan assay were assessed. For drugs that tested positive, the minimal concentration of the antibiotic in serum that yielded a positive test (index, >0.5) was determined. At undiluted concentrations, piperacillin and multiple lots of piperacillin-tazobactam tested positive, whereas amoxicillin, ampicillin-sulbactam, nafcillin, cefazolin, ceftazidime, erythromycin, gentamicin, and levofloxacin tested negative. All three lots of piperacillin-tazobactam and all bags within each lot tested positive, with a mean index value of 5.168. At achievable concentrations in serum, however, only one of three lots of piperacillin-tazobactam yielded a positive test. Concentrations of 75, 150, and 300 microg/ml of serum tested positive with the Platelia Aspergillus enzyme immunoassay, whereas lower concentrations, mimicking the trough levels, tested negative. Thus, while achievable serum piperacillin-tazobactam concentrations may potentially result in a positive test for galactomannan, the timing of the collection of serum samples from patients may influence the test results, with reactivity being less likely in samples collected at trough levels or prior to the administration of a dose of the antibiotic.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15155189      PMCID: PMC415629          DOI: 10.1128/AAC.48.6.1989-1992.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam.

Authors:  Annie Sulahian; Sophie Touratier; Patricia Ribaud
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

2.  Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients.

Authors:  Eun Jeong Kwak; Shahid Husain; Asia Obman; Lisa Meinke; Janet Stout; Shimon Kusne; Marilyn M Wagener; Nina Singh
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

3.  Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies.

Authors:  Olivier Adam; Anne Aupérin; Fanny Wilquin; Jean-Henri Bourhis; Bertrand Gachot; Elisabeth Chachaty
Journal:  Clin Infect Dis       Date:  2004-02-27       Impact factor: 9.079

4.  A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis.

Authors:  D Stynen; A Goris; J Sarfati; J P Latgé
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

5.  Classics in infectious diseases: on the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae by Alexander Fleming, Reprinted from the British Journal of Experimental Pathology 10:226-236, 1929.

Authors:  A Fleming
Journal:  Rev Infect Dis       Date:  1980 Jan-Feb

6.  The 5-O-beta-D-galactofuranosyl-containing peptidophosphogalactomannan of Penicillium charlesii. Characterization of the mannan by 13C NMR spectroscopy.

Authors:  C J Unkefer; J E Gander
Journal:  J Biol Chem       Date:  1990-01-15       Impact factor: 5.157

7.  Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis.

Authors:  A Sulahian; M Tabouret; P Ribaud; J Sarfati; E Gluckman; J P Latgé; F Derouin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-02       Impact factor: 3.267

8.  Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus.

Authors:  J P Latgé; H Kobayashi; J P Debeaupuis; M Diaquin; J Sarfati; J M Wieruszeski; E Parra; J P Bouchara; B Fournet
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

9.  Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients.

Authors:  Shahid Husain; Eun Jeong Kwak; Asia Obman; Marilyn M Wagener; Shimon Kusne; Janet E Stout; Kenneth R McCurry; Nina Singh
Journal:  Am J Transplant       Date:  2004-05       Impact factor: 8.086

10.  Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis.

Authors:  P Rohrlich; J Sarfati; P Mariani; M Duval; A Carol; C Saint-Martin; E Bingen; J P Latge; E Vilmer
Journal:  Pediatr Infect Dis J       Date:  1996-03       Impact factor: 2.129

View more
  13 in total

Review 1.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

2.  Galactomannan in piperacillin-tazobactam: how much and to what extent?

Authors:  Marco Machetti; Elisa Furfaro; Claudio Viscoli
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

3.  Cross-reactivity of Paracoccidioides brasiliensis, Histoplasma capsulatum, and Cryptococcus species in the commercial Platelia Aspergillus enzyme immunoassay.

Authors:  Melissa O Xavier; Alessandro C Pasqualotto; Isabel Cristina E Cardoso; Luiz Carlos Severo
Journal:  Clin Vaccine Immunol       Date:  2008-11-19

4.  Detection of Aspergillus galactomannan antigenemia to determine biological and clinical implications of beta-lactam treatments.

Authors:  Emmanuelle Bart-Delabesse; Maria Basile; Ahmad Al Jijakli; Didier Souville; Frédérick Gay; Bruno Philippe; Philippe Bossi; Martin Danis; Jean-Paul Vernant; Annick Datry
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

5.  Comparison of galactomannan detection, PCR-enzyme-linked immunosorbent assay, and real-time PCR for diagnosis of invasive aspergillosis in a neutropenic rat model and effect of caspofungin acetate.

Authors:  Jennifer M Scotter; Stephen T Chambers
Journal:  Clin Diagn Lab Immunol       Date:  2005-11

6.  Generic piperacillin/tazobactam is not associated with galactomannan false-positivity in adult patients with cancer: a case-control study.

Authors:  J-H Ko; K R Peck; W J Lee; J Y Lee; S Y Cho; Y E Ha; C-I Kang; D R Chung; C W Jung; E-S Kang; J-H Song
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-17       Impact factor: 3.267

7.  Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections.

Authors:  Jerry W Pickering; Howard W Sant; Catherine A P Bowles; William L Roberts; Gail L Woods
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

8.  Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders.

Authors:  Alban Aubry; Raphael Porcher; Julie Bottero; Sophie Touratier; Thierry Leblanc; Benoît Brethon; Philippe Rousselot; Emmanuel Raffoux; Jean Menotti; Francis Derouin; Patricia Ribaud; Annie Sulahian
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

9.  False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment.

Authors:  Daniele Mattei; Davide Rapezzi; Nicola Mordini; Federica Cuda; Cristiana Lo Nigro; Maura Musso; Aldo Arnelli; Sebastiano Cagnassi; Andrea Gallamini
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

10.  Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis.

Authors:  Randall Hayden; Stanley Pounds; Katherine Knapp; Ruta Petraitiene; Robert L Schaufele; Tin Sein; Thomas J Walsh
Journal:  Pediatr Infect Dis J       Date:  2008-09       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.